New Phase 2 Data With Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA® (pembrolizumab) in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting

IRVINE, Calif.–(BUSINESS WIRE)– #AUA2023–New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA® in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting